NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwire - November 05, 2012) -
Regenerative medicine company Avita Medical Ltd.
(ASX: AVH) (OTCQX: AVMXY
) today announced that it will be presenting at the upcoming SoCalBio Investor Conference & Exhibition. The event will take place on November 7, 2012 at the Omni Hotel in Los Angeles, California.
The Company will be presenting in the Wound Healing & Regenerative Medicine Group.
"We are pleased to be presenting at this quality bioscience industry conference," said Dr. William Dolphin, Avita Medical's CEO. "ReCell® Spray-On Skin™ is on the market in other countries and undergoing FDA clinical trials in the US. This conference is a great venue to generate awareness among the US investment community as we approach FDA submission."
This is a one-day conference organized annually by the Southern California Biomedical Council (SoCalBio) to showcase the strength and future of the bioscience industry in Los Angeles/Orange County and neighboring communities. For more information on the conference: http://www.socalbio.org/SocalBio_2012/home_2012.htm
ABOUT AVITA MEDICAL LTD.
Avita Medical (http://www.avitamedical.com/) develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell® Spray-On Skin™, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is on market and generating early revenues. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.